December 22, 2016 - Supra Research and Development has received verification from Health Canada that the Controll Substance Dealer's License for Supra THC Services has been granted and will be in effect on January 1, 2017.
December 16, 2016 - Supra Research and Development confirms that it has signed a termination agreement ending the joint venture with THC Biomed Int'l Ltd. originally signed on February 12, 2016.
For further details, please read the full press release.
Supra Research and Development is pleased to announce that we are now offering analytical services to ACMPR clients under our Health Canada Dealers License.
Supra Research and Development is an independently owned and operated analytical firm with no ties to any Licenced Producer. All work with LP's is undertaken strictly as an independent 3rd party service provider.
Dr. Rob O'Brien, the President and CTO of Supra Research and Development as well as the Chief Science Officer of Supra THC Services, also has no formal affiliation to any Licensed Producer.
Full details including analyses offered as well as pricing and information regarding how to obtain services can be found on our ACMPR page.